Following a hold-up and a particularly heated session, a federal vaccine advisory panel was scheduled to decide on Friday concerning altering the enduring advisory that each baby be immunized against hepatitis B.
Heated Debate and a Delayed Ballot
The opening session of the conference on Thursday was characterized by intense argument over curbing eligibility to the hepatitis B vaccine for infants and a decision to postpone the decision by a day to allow panelists additional time to review the wording. The committee, which guides the CDC on immunization practices, had twice before postponed.
“Is there any specific evidence of injury of giving this vaccination before 30 days? Or is this conjecture?” inquired one adviser.
In answer, another participant stated, “There is inadequate data about the prolonged hazard.”
Existing Recommendations and Likely Ramifications
The injection is currently suggested for every newborn within 24 hours of being born to prevent infection of hepatitis B, which can cause major damage to the liver. It has been provided to over a billion individuals for more than three decades.
The Atlanta conference provided no recent proof of injuries resulting from the vaccine. Authorities state any modification to the present hepatitis B vaccination schedule could have significant and far-reaching consequences for childhood health in the United States.
Panel Composition and New Appointments
The consultative group can only make recommendations to the director of the CDC. The panel's membership has seen shifts in recent days, with the announcement that the committee’s most recent chair would step down for an formal position and be substituted with a heart specialist who has been skeptical about other vaccines.
The committee includes several vaccine skeptics who support a aim to revamp – and potentially, in some cases, scrap – longstanding vaccination recommendations.